GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lineage Cell Therapeutics Inc (XTAE:LCTX) » Definitions » PB Ratio

Lineage Cell Therapeutics (XTAE:LCTX) PB Ratio : 2.78 (As of May. 16, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Lineage Cell Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-16), Lineage Cell Therapeutics's share price is ₪3.937. Lineage Cell Therapeutics's Book Value per Share for the quarter that ended in Mar. 2024 was ₪1.41. Hence, Lineage Cell Therapeutics's PB Ratio of today is 2.78.

The historical rank and industry rank for Lineage Cell Therapeutics's PB Ratio or its related term are showing as below:

XTAE:LCTX' s PB Ratio Range Over the Past 10 Years
Min: 0.64   Med: 3.05   Max: 29.45
Current: 2.84

During the past 13 years, Lineage Cell Therapeutics's highest PB Ratio was 29.45. The lowest was 0.64. And the median was 3.05.

XTAE:LCTX's PB Ratio is ranked worse than
55.14% of 1322 companies
in the Biotechnology industry
Industry Median: 2.54 vs XTAE:LCTX: 2.84

During the past 12 months, Lineage Cell Therapeutics's average Book Value Per Share Growth Rate was -7.20% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -16.80% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -14.30% per year. During the past 10 years, the average Book Value Per Share Growth Rate was 1.80% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Lineage Cell Therapeutics was 63.80% per year. The lowest was -167.40% per year. And the median was -9.70% per year.

Back to Basics: PB Ratio


Lineage Cell Therapeutics PB Ratio Historical Data

The historical data trend for Lineage Cell Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lineage Cell Therapeutics PB Ratio Chart

Lineage Cell Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.02 2.41 3.86 2.47 2.93

Lineage Cell Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.45 3.29 3.25 2.93 3.65

Competitive Comparison of Lineage Cell Therapeutics's PB Ratio

For the Biotechnology subindustry, Lineage Cell Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lineage Cell Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lineage Cell Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Lineage Cell Therapeutics's PB Ratio falls into.



Lineage Cell Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Lineage Cell Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2024)
=3.937/1.414
=2.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Lineage Cell Therapeutics  (XTAE:LCTX) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Lineage Cell Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of Lineage Cell Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Lineage Cell Therapeutics (XTAE:LCTX) Business Description

Traded in Other Exchanges
Address
2173 Salk Avenue, Suite 200, Carlsbad, CA, USA, 92008
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cell transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Lineage Cell Therapeutics (XTAE:LCTX) Headlines

From GuruFocus